EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

A potential immunosuppressive role for vasoactive intestinal peptide (VIP) in leishmaniasis: evidence from the use of a selective VIP antagonist


Current Science 64(7): 521-524
A potential immunosuppressive role for vasoactive intestinal peptide (VIP) in leishmaniasis: evidence from the use of a selective VIP antagonist
The immunological role of vasoactive intestinal peptide (VIP) in the pathology of leishmaniasis in BALB/c mice is examined. Mice were primed subcutaneously with washed, killed promastigotes of Leishmania donovani and L. tropica then challenged 7 days later with the antigen. Two, 4 and 6 weeks post-priming mice were sacrificed and the splenic cells tested for the ability to respond to Con A.


Accession: 002287111



Related references

Study of species specificity in growth hormone releasing factor interaction with vasoactive intestinal peptide receptors using growth hormone releasing factor and intestinal vasoactive intestinal peptide receptors from rat and human evidence that acetyl 1 tyrosine human growth hormone releasing hormone is a competitive vasoactive intestinal peptide antagonist in the rat. Molecular Pharmacology 29(1): 23-27, 1986

Evidence for common precursors but differential processing of vasoactive intestinal peptide and peptide histidine methionine in vasoactive intestinal peptide producing tumors. Peptides (New York) 6(3): 357-362, 1985

A fragment of vasoactive intestinal peptide 10 28 is an antagonist of vasoactive intestinal peptide in the colon carcinoma cell line ht 29. Peptides (New York) 7(5): 849-854, 1986

Vasoactive intestinal peptide 10 28 is an antagonist of vasoactive intestinal peptide adenylate cyclase stimulation in ht 29 cells. Society for Neuroscience Abstracts 11(1): 414, 1985

Vasoactive intestinal peptide receptor antagonist 6 tetrachloro d phenylalanine 17 leucine vasoactive intestinal peptide. American Journal of Physiology 250(4 PART 1): G553-G557, 1986

Vasoactive intestinal peptide-mediated suppression of apoptosis in the ovary: potential mechanisms of action and evidence of a conserved antiatretogenic role through evolution. Endocrinology 136(10): 4351-4359, 1995

Vasoactive intestinal peptide- and adrenocorticotropin-stimulated adenyl cyclase in cultured adrenal tumor cells: evidence for a specific vasoactive intestinal peptide receptor. Endocrinology 106(4): 1270-1275, 1980

Creation of a selective antagonist and agonist of the rat VPAC(1) receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template. Molecular Pharmacology 58(5): 1035-1041, 2000

Species specificity in growth hormone releasing factor interaction with vasoactive intestinal peptide receptors discovery of a competitive vasoactive intestinal polypeptide antagonist. Regulatory Peptides (SUPPL 3): S32, 1985

Role of vasoactive intestinal peptide in the control of prolactin-induced turkey incubation behavior. I. Acute infusion of vasoactive intestinal peptide. Biology of Reproduction 50(6): 1344-1349, 1994